Goldman Sachs
NVLN

Goldman Sachs’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Goldman Sachs’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-206,782
Closed -$150K – 5568
2019
Q3 		$150K Sell
206,782
-51,892
-20% -$37.6K ﹤0.01% 4900
2019
Q2 		$202K Buy
+258,674
New +$288K ﹤0.01% 4791
2018
Q4 		– Sell
-51,462
Closed -$152K – 5891
2018
Q3 		$152K Sell
51,462
-166,611
-76% -$590K ﹤0.01% 4997
2018
Q2 		$803K Buy
218,073
+206,897
+1,851% +$831K ﹤0.01% 4223
2018
Q1 		$39K Buy
11,176
+1,110
+11% +$4.71K ﹤0.01% 5544
2017
Q4 		$31K Sell
10,066
-9,309
-48% -$44.7K ﹤0.01% 6040
2017
Q3 		$136K Sell
19,375
-91,850
-83% -$736K ﹤0.01% 5948
2017
Q2 		$1.03M Sell
111,225
-1,677
-1% -$16.1K ﹤0.01% 4431
2017
Q1 		$1.21M Buy
112,902
+1,889
+2% +$19.3K ﹤0.01% 4210
2016
Q4 		$935K Buy
+111,013
New +$983K ﹤0.01% 4516

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Goldman Sachs's NVLN Position: Q4 2019 in Review

Goldman Sachs sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 206,782 shares — an estimated $150K sold.

Goldman Sachs first reported a position in NVLN in Q4 2016 and held it in 10 quarters. The position peaked at $1.21M in Q1 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Goldman Sachs reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 206,782 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $150K.
  • Goldman Sachs first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 10 quarters.
  • Goldman Sachs's Novelion Therapeutics Inc. Common Shares position peaked at $1.21M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.